{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:45:03Z","timestamp":1782783903553,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pediatric acute myeloid leukemia (AML) is biologically heterogeneous, and genomic profiling increasingly informs risk stratification and treatment. We evaluated the relationship between induction response, genomic risk, transplant allocation, and survival in pediatric AML. We retrospectively analyzed 38 pediatric patients with newly diagnosed AML, treated between 2020 and 2025. Clinical, cytogenetic, molecular, treatment, and outcome data were collected. Genomic alterations were assessed using cytogenetics, fluorescence in situ hybridization (FISH), molecular testing, and next-generation sequencing (NGS). Survival was estimated by Kaplan\u2013Meier analysis, and prognostic factors for event-free survival (EFS) were assessed using univariable Cox regression. This study is exploratory given the limited sample size and should be interpreted accordingly. Complete remission (CR) after the first course of induction was achieved in 25\/38 patients (65.8%), partial remission (PR) in 3\/38 (7.9%), and refractory disease in 10\/38 (26.3%). Twenty-four patients underwent allogeneic hematopoietic stem cell transplantation; 17\/24 (70.8%) were alive at last follow-up, with a 2-year overall survival rate of 72.9%. Both induction response and genomic risk stratification showed suggestive associations with outcome; descriptively, induction response showed the strongest prognostic discrimination, with achievement of CR associated with markedly improved survival. High cytogenetic risk and FLT3-ITD were significantly associated with inferior EFS. Post-induction measurable residual disease (MRD) positivity was detected in 16 of 38 patients (42.1%) and was associated with suboptimal induction response; MRD negativity did not uniformly preclude adverse outcomes, particularly in the high-risk genomic subgroup. Genomic profiling refined biological risk and post-remission treatment allocation. Integrated assessment of genomic risk, induction response, and MRD status may improve therapeutic stratification in pediatric AML.<\/jats:p>","DOI":"10.3390\/ijms27135832","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"5832","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic Profiling, Induction Response, and Transplant Outcomes in Pediatric Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study"],"prefix":"10.3390","volume":"27","author":[{"given":"Ana Maria","family":"Bic\u01ce","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-6620","authenticated-orcid":false,"given":"Andra Daniela","family":"Marcu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-5859","authenticated-orcid":false,"given":"Cristina Georgiana","family":"Jercan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Iordan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-5479","authenticated-orcid":false,"given":"Leti\u021bia Elena","family":"Radu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3253-7341","authenticated-orcid":false,"given":"Irina","family":"Avramescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerasela","family":"Jardan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Hematology Laboratory, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Jardan","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, MedLife, 010719 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onda Tabita","family":"C\u01celug\u01ceru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Hematology Laboratory, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Mocanu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Coli\u021b\u01ce","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Hematology, Col\u021bea Hospital, 050098 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-8190","authenticated-orcid":false,"given":"Anca","family":"Coli\u021b\u01ce","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41591-019-0369-7","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"25","author":"Bolouri","year":"2019","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.2024027904","article-title":"Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel","volume":"147","author":"Zwaan","year":"2025","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pcl.2014.09.007","article-title":"Pediatric acute myeloid leukemia: Biology and therapeutic implications of genomic variants","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr. Clin. North Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tseng, S., Lee, M.-E., and Lin, P.-C. (2023). A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. Pharmaceuticals, 16.","DOI":"10.3390\/ph16111614"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e180065","DOI":"10.1172\/JCI180065","article-title":"Clonal hematopoiesis and hematological malignancy","volume":"134","author":"Dunn","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s42003-023-04732-2","article-title":"Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia","volume":"6","author":"Cheng","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","article-title":"The genomics of acute myeloid leukemia in children","volume":"39","author":"Conneely","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Le\u015bniak, M., Sekunda, A., Kamizela, E., Deleszkiewicz, P., Ozyga\u0142a, A., Zawitkowska, J., and Lejman, M. (2025). A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199269"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Choi, H.S., Kim, B.S., Yoon, S., Oh, S.O., and Lee, D. (2024). Leukemic Stem Cells and Hematological Malignancies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126639"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1182\/bloodadvances.2024014728","article-title":"Improved outcomes and treatment guidance in pediatric AML","volume":"9","author":"Sendker","year":"2025","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Huang, L., Peng, X., Shu, W., Shi, H., Xiao, L., Liu, T., Xiang, Y., Guo, Y., Guan, X., and Li, J. (2025). Unveiling the Genetic Mosaic of Pediatric AML: Insights from Southwest China. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110605"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Boscaro, E., Urbino, I., Catania, F.M., Arrigo, G., Secreto, C., Olivi, M., D\u2019Ardia, S., Frairia, C., Giai, V., and Freilone, R. (2023). Modern risk stratification of acute myeloid leukemia in 2023: Integrating established and emerging prognostic factors. Cancers, 15.","DOI":"10.3390\/cancers15133512"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tomizawa, D., and Tsujimoto, S.-I. (2023). Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15164171"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/08880018.2025.2453861","article-title":"Pediatric AML: State of the Art and Future Directions","volume":"42","author":"Iyer","year":"2025","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bertuccio, S.N., Anselmi, L., Masetti, R., Lonetti, A., Cerasi, S., Polidori, S., Serravalle, S., and Pession, A. (2021). Exploiting Clonal Evolution to Improve the Diagnosis and Treatment Efficacy Prediction in Pediatric AML. Cancers, 13.","DOI":"10.3390\/cancers13091995"},{"key":"ref_23","first-page":"64","article-title":"Genetic heterogeneity and clonal evolution in acute myeloid leukemia","volume":"28","author":"Meyer","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Rao, M., Luo, W., Luo, C., Wu, B., Xu, T., Wei, Z., Deng, H., Li, K., and Zhou, D. (2025). Prognostic factors and outcomes in pediatric acute myeloid leukemia: A comprehensive bibliometric analysis of global research trends. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1466818"},{"key":"ref_25","unstructured":"Tripathi, A.K., and Chuda, R. (2026, April 16). Laboratory Evaluation of Acute Leukemia, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK611988\/table\/article-145918.table1\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","article-title":"Structural and functional alterations of FLT3 in acute myeloid leukemia","volume":"15","author":"Meshinchi","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"ref_29","first-page":"2553","article-title":"The challenges of managing acute myeloid leukemia in pediatric patients: A review of current treatment strategies","volume":"13","author":"Verma","year":"2025","journal-title":"Int. J. Res. Med. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Albakri, M.M. (2025). TP53-mutated MDS and AML: Immune dysregulation, tumor microenvironment, and emerging therapeutic strategies. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1655486"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1182\/bloodadvances.2020002457","article-title":"Fusion partner\u2013specific mutation profiles in MLL AML","volume":"4","author":"Matsuo","year":"2020","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/tp.2019.12.03","article-title":"Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia","volume":"9","author":"Ney","year":"2020","journal-title":"Transl. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: Revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/leu.2008.313","article-title":"Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML","volume":"23","author":"Hollink","year":"2009","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12185-023-03533-x","article-title":"Comprehensive molecular understanding of pediatric acute myeloid leukemia","volume":"117","author":"Shiba","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_37","first-page":"701","article-title":"Maximal benefit of minimal residual disease monitoring in pediatric acute myeloid leukemia","volume":"109","author":"Hasle","year":"2024","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). Documentation of Engraftment and Chimerism After HCT. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, Springer. [8th ed.].","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Marcu, A.D., Jercan, C.G., Bica, A.M., Serbanica, A.N., Radu, L.E., Avramescu, I., Mocanu, A., Niculita, O.O., Popa, D.C., and Jardan, C. (2025). Conditioning regimens in pediatric myeloid malignancies undergoing allogeneic HSCT: A comparative single-center study. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1623636"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bica, A.M., Marcu, A.D., Jercan, C.G., Iordan, I., Serbanica, A.N., Avramescu, I., Colita, M., Popa, D.C., Constantinescu, I., and Ichim, A.M. (2025). Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: A single-center retrospective analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1727492"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). Acute Graft-Versus-Host Disease. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet], Springer. [8th ed.]. Chapter 43.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_42","first-page":"2275","article-title":"Relapsed pediatric acute myeloid leukaemia: State-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5832\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:11:26Z","timestamp":1782781886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":42,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135832"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135832","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}